Premium
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non‐erosive gastro‐oesophageal reflux disease
Author(s) -
Fujiwara Y.,
Higuchi K.,
Nebiki H.,
Chono S.,
Uno H.,
Kitada K.,
Satoh H.,
Nakagawa K.,
Kobayashi K.,
Tominaga K.,
Watanabe T.,
Oshitani N.,
Arakawa T.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02468.x
Subject(s) - medicine , omeprazole , famotidine , reflux , gastro , randomized controlled trial , gastroenterology , esophageal disease , disease , prospective cohort study , gerd , esophagus
Summary Background : Several studies in Western countries showed that proton‐pump inhibitors are superior to histamine 2 ‐receptor antagonists or placebo in the treatment of non‐erosive gastro‐oesophageal reflux disease. The efficacy of acid‐suppressive drugs for non‐erosive gastro‐oesophageal reflux disease in Japan, in which the prevalence of Helicobacter pylori infection is higher compared with Western countries, is unknown. Aim : To compare the efficacy of famotidine and omeprazole in Japanese patients with non‐erosive gastro‐oesophageal reflux disease by a prospective randomized multicentre trial. Methods : A total of 98 patients received either famotidine 20 mg b.d. ( n = 48) or omeprazole once daily ( n = 50). Frequency of gastro‐oesophageal reflux disease symptoms and health‐related quality of life were evaluated at baseline and after 4 weeks of treatment. Complete relief was defined as no gastro‐oesophageal reflux disease symptoms during the 7‐day interval in week 4. Results : Complete relief was achieved in 23 (48%) of patients receiving famotidine and 28 (56%) of patients treated with omeprazole. In the famotidine group, complete relief rate in H. pylori ‐negative patients was significantly lower than H. pylori ‐positive patients (35% vs. 64%). Both famotidine and omeprazole improved most scales of health‐related quality of life. Omeprazole significantly improved reflux score irrespective of H. pylori infection while famotidine significantly improved reflux score in H. pylori ‐positive patients but not in H. pylori ‐negative patients. Conclusions : Omeprazole is more effective than famotidine for the control of gastro‐oesophageal reflux disease symptoms in H. pylori ‐negative patients, while similar efficacy is observed in H. pylori ‐positive patients with non‐erosive gastro‐oesophageal reflux disease.